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Abstract
Feline diabetes mellitus shares many features with type 2 diabetes in people, regarding clini-
cal presentation, physiology, and pathology. A breed predisposition for type 2 diabetes has
been identified, with the Burmese breed at a fivefold increased risk of developing the condi-
tion compared to other purebred cats. We aimed to characterize the serum metabolome in
cats (n = 63) using nuclear magnetic resonance metabolomics, and to compare the metabo-
lite pattern of Burmese cats with that of two cat breeds of medium or low risk of diabetes, the
Maine coon (MCO) and Birman cat, respectively. Serum concentrations of adiponectin,
insulin and insulin-like growth factor-1 were also measured (n = 94). Burmese cats had
higher insulin and lower adiponectin concentrations than MCO cats. Twenty one metabolites
were discriminative between breeds using a multivariate statistical approach and 15
remained significant after adjustment for body weight and body condition score. Burmese
cats had higher plasma levels of 2-hydroxybutyrate relative to MCO and Birman cats and
increased concentrations of 2-oxoisocaproic acid, and tyrosine, and lower concentrations of
dimethylglycine relative to MCO cats. The metabolic profile of MCO cats was characterized
by high concentrations of arginine, asparagine, methionine, succinic acid and low levels of
acetylcarnitine while Birman cats had the highest creatinine and the lowest taurine plasma
levels, compared with MCO and Burmese. The pattern of metabolites in Burmese cats is
similar to that in people with insulin resistance. In conclusion, the metabolic profile differed
between healthy cats of three breeds. Detection of an abnormal metabolome might identify
cats at risk of developing diabetes.
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Introduction
Diabetes mellitus (DM) is an increasingly common endocrinopathy in cats and has many fea-
tures in common with human type 2 diabetes (T2DM) [1, 2]. Cats and humans share many
risk factors for developing the disease, for example, the association with insulin resistance
(IR) coupled to obesity and a sedentary lifestyle, and β-cell loss with amyloid deposition in
the islets of Langerhans in the pancreas [3–6]. There is a genetic predisposition in both peo-
ple [7–9] and cats, with the Burmese cat breed at increased risk [10–13]. An inherited dyslipi-
demia has been suggested to increase IR and predispose Burmese cats to the disease [14].
Abnormally increased serum triglyceride (TG) concentrations after oral fat tolerance test
have been described [15], indicating a delayed clearance of TG compared to unaffected Bur-
mese cats. In people, hypertriglyceridemia has been associated with both IR and T2DM [16–
20]. Hypertriglyceridemia is also one of the components of the metabolic syndrome in peo-
ple, together with central obesity, increased blood pressure and IR [21]. People with meta-
bolic syndrome have a fivefold increased risk of developing T2DM [22]. Subsequent studies
have described aberrations in the cholesterol lipoprotein fraction profiles in lean Burmese
cats, similar to obese cats, with increases in very low-density lipoprotein (VLDL) concentra-
tions, and decreases in high-density lipoproteins (HDL), a pattern similar to the metabolic
syndrome in people [23–26]. In addition, the expression patterns of several genes involved in
lipid metabolism as well as low circulating adiponectin concentrations in lean Burmese cats
resemble those of obese cats. In people, low adiponectin levels are associated with IR and
T2DM [27–31].
Metabolites are small molecules that are chemically transformed in the metabolism and
provide functional readouts of cellular biochemical activities. The metabolome provides a
measurement of the metabolic phenotype that is a net result of genomic, transcriptomic, and
proteomic variability [32]. Metabolomics is useful for studying metabolic diseases, or traits,
such as T2DM and IR, especially considering that the more than 100 so far identified T2DM
associated gene loci in people have only small to moderate effects on the individual’s suscepti-
bility to the disease [33]. Metabolomics has been utilized in diabetes research in people [34–
40], and an abnormal pattern in the branched-chain and aromatic amino acids has been
described [41–44]. Few studies using the metabolomics approach are available in cats. The
metabolome of cats in remission has been studied and compared to that of control cats, show-
ing an abnormal metabolism in cats in remission [45]. In a PhD thesis the metabolome has
been shown to differ between obese and normal weight cats, and between senior cats of Bur-
mese compared to those of other breeds [46]. In studies not related to DM, one study analyzed
the urine metabolome using gas chromatography/time-of-flight mass spectrometry in eight
healthy domestic cats [47], and in another study the effects of dietary macronutrient composi-
tion on the plasma metabolome of healthy adult cats were assessed with liquid chromatogra-
phy followed by mass spectrometry (LC/MS) [48].
The objective of the present study was to characterize the feline metabolic profile in healthy
Burmese cats, and compare it to two cat breeds of medium or low risk for developing DM, the
Maine coon (MCO) and Birman cat, respectively, [11] by using nuclear magnetic resonance
(NMR) metabolomics, serum biochemistry, and hormone immunoassays. Differences in the
metabolome of these three feline breeds might shed light into preventative measures in the
future under a clinical setting. The information may be used when metabolome perturbations
of a patient begin to emerge and can be compared to known disease associated metabolome
profiles.
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Materials and methods
Study population
The study was approved by the Uppsala Ethical Committee on Animal Research (C 299/12
and C 12/15) and the Swedish Board of Agriculture (31-11654/12), and written informed con-
sent to participate in the study was obtained from all owners.
Healthy, adult (> 1 year), purebred, client-owned cats (n = 106) of three different breeds
(Burmese, MCO and Birman) were included in the study. Food was withheld for at least 12
hours prior to sampling. Cats were weighed and a physical examination including body condi-
tion scoring using a 9-grade scale [44] was performed by a veterinarian at the University
Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden, or the Bagar-
mossen Anicura Referral Hospital, Stockholm, Sweden. Of the Burmese cats, 31 cats were sam-
pled in 2013. All other cats were sampled 2015–2016. Cats with a body condition score (BCS)
between 3 and 4 were grouped as underweight, 5 were considered normal weight, and cats
with a BCS between 6 and 9 were grouped as overweight [47]. Owners completed a question-
naire which included questions concerning the cat’s age, breed, sex, neutering status, any cur-
rent or previous medications or medical issues, and time of last meal.
Cats were excluded if they were non-fasted, non-compliant at sampling, had a history of or
ongoing severe organ related or systemic disease, or if they had received progestin or cortico-
steroid treatments during the last year. Cats were also excluded if serum biochemistry showed
values clearly outside the reference range, although small deviations in fasting serum creati-
nine levels were accepted [48]. Fasting serum concentrations of creatinine�200 μmol/L, ala-
nine aminotransferase (ALAT)�2.8 μkat/L, and fructosamine�350 μmol/L were accepted.
Sampling
Blood was drawn from the cephalic vein and collected into serum tubes. Samples were centri-
fuged for 10 minutes at 3000 rpm and serum was thereafter aliquoted and stored cool and ana-
lyzed within 24 hours, or stored in microtubes at -70˚C until further analysis.
Analyses
Serum biochemistry. All serum samples were analyzed for ALAT, creatinine, and fructo-
samine concentrations on an automated chemistry analyzer (Abbott Architect c4000, Abbott
Park, IL, USA) at the Clinical Pathology Laboratory, University Animal Hospital, Swedish
University of Agricultural Sciences, Uppsala, Sweden.
Lipoprotein profiles were obtained at the department of Medical Biosciences, Umeå Uni-
versity by utilizing an automated HPLC system (Elite LaChrom, Hitachi, Krefeld, Germany)
with a Superose 6 size-exclusion column (GE Healthcare, Uppsala, Sweden). Plasma samples
were diluted 1:16 in elution buffer that consisted of 10 mM Tris, 150 mM NaCl and 0,02%
NaN3, and injected into the column. On-line measurements of triglyceride and cholesterol
concentrations were performed using appropriate reagents (Roche, Basel, Switzerland). The
reagents were diluted 1:2 with lab grade water prior to analyses. As a standard for lipoprotein
profiles, a human plasma sample with a known lipid concentration was used. All data was pro-
cessed using the EZChrom Elite software (Agilent Technologies, Boeblingen, Germany).
Free fatty acids were measured with the MaxDiscovery™ Non-esterified fatty acids (NEFA)
Assay Kit (Bioo Scientific, Austin TX, US), at the Clinical Sciences laboratory, Swedish Univer-
sity of Agricultural Sciences, Uppsala, Sweden.
Hormone immunoassays. Total adiponectin concentrations were assayed using the Adi-
ponectin Human ELISA, High Sensitivity (BioVendor—Laboratorni medicina, Brno, Czech
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Republic), insulin concentrations were measured with the Mercodia Feline Insulin ELISA
(Mercodia AB, Uppsala, Sweden), and insulin-like growth factor (IGF)-1 with the human E20
Insulin-like Growth Factor-I ELISA (Mediagnost, Reutlingen, Germany). All analyses were
performed in duplicate at the Department of Clinical Sciences laboratory, Swedish University
of Agricultural Sciences, Uppsala, Sweden. All hormonal assays have previously been validated
for use in cats [49–52]. If the intra-assay coefficient of variation (CV) was above 10%, samples
were rerun, and the highest accepted CV was 11% (one sample). For IGF-1, samples at concen-
trations above 28 ng/mL on the standard curve were diluted further and rerun, to avoid inter-
ference by IGF-binding proteins, which may not be efficiently removed when using the
standard protocol [51].
NMR-based metabolomics analyses. Metabolomics analyses were performed on a subset
of samples, all collected 2015–2016 (in total n = 63; Burmese n = 15, MCO n = 25, Birman
n = 23,). Nanosep centrifugal filters with 3-kDa cutoff (Pall Life Science, Port Washington,
NY) were washed to remove glycerol from the filter membrane. 60 μl serum were filtered at
10,000 g, 4˚C. 40 μl of filtrate were mixed with 50 μl phosphate buffer (0.4 mol/L, pH 7.0),
15 μl D2O, 55 μl millipore water, and 10 μl sodium-3-(trimethlsilyl)-2,2,3,3,-tetradeuteriopro-
pionate (TSP, 5.8 mmol/L) (Cambridge Isotope Laboratories, Andover, MA) as an internal
standard to be able to quantify metabolites. Analyses were performed on a Bruker spectrome-
ter operating at 600 MHz equipped with a cryogenically cooled probe and auto sampler at the
Department of Molecular Sciences, Swedish University of Agricultural Sciences, Uppsala, Swe-
den. The 1H NMR spectra were obtained using zgesgp pulse sequence (Bruker Spectrospin
Ltd) at 25˚C with 512 scans at 65,356 data points over a spectral width of 17,942.58 Hz (acqui-
sition time: 1.83 s, relaxation delay 4 s). Baseline and spectral phase correction were performed
manually using Chenomx. The line width was adjusted to 1.1 Hz for all spectra. Fifty-eight
metabolites were identified and their concentrations were calculated using an automated
quantification algorithm (AQuA) accounting for interfering signals as previously described
[53].
Statistical analysis
Normally distributed data are reported as mean with standard deviation (SD), and non-nor-
mally distributed data as median with interquartile range (IQR). A one-way ANOVA was used
to compare age, sex, body weight (BW) and BCS between breeds. The assumption of normally
distributed residuals and equal variances in the model was examined by visual inspection of
diagnostic plots (histogram of residuals and normal probability plots of residuals). If residuals
were not normally distributed, data were log-transformed and diagnostic plots were reevalu-
ated. If residuals remained non-normally distributed, a non-parametric test was used.
To assess differences in metabolites between breeds, univariate statistical analyses were per-
formed (Minitab, version 17.3.1) on metabolites identified as discriminative via the multivari-
ate approach described below by using one-way ANOVA (for normally distributed data), or
Kruskal-Wallis test (for not normally distributed data). Further, the Tukey’s post hoc test was
applied to assess differences between the three breeds. To adjust for influence of BW and BCS,
a univariate mixed linear regression model was applied, for each metabolite identified as dis-
criminative between breeds (SAS, version 9.4). Concentrations are reported as least square
means or geometric means with 95% CI as described above. The significance level was set at
P< 0.05.
Multivariate regression was used to investigate the effects of breed, BW, and BCS on the
concentrations of creatinine, ALAT, fructosamine, VLDL-TG, HDL-cholesterol, FFA, insulin,
adiponectin, and IGF-1 using SAS (version 9.4). Potential interactions were controlled for by
PLOS ONE Differences in metabolic profiles between three cat breeds with varying risk for diabetes mellitus
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including interaction factors between the explanatory variables. Concentrations were reported
as least square means with 95% CI, and if data were logged for analysis, least square means
were back-transformed and reported as geometric means with 95% CI. P-values given for the
multivariate analyses are based on Wilk’s lambda. Effects of differences in storage time and
sample handling were evaluated by t-test within the Burmese breed group, where samples were
collected during two different time periods (2013, and 2015 to 2016, respectively).
Multivariate statistical analyses were performed on metabolomics data using SIMCA 14
software (Umetrics, Umeå, Sweden). Principal component analysis (PCA) was applied to get
an overview of the data and to exclude potential outliers by using the PCA-Hotelling’s T2
Ellipse (95% confidence intervals (CI)). To assess differences between the breeds, partial least
square discriminant analysis (PLS-DA) was applied, which can take class membership (e.g. cat
breed) into account. To determine discriminative metabolites between the breeds, variable
influences on projection (VIP) values were used. Metabolites with VIP values > 1 for which
the corresponding jackknife-based 95% CIs were not close to or included zero were considered
discriminative. Cross-validated ANOVA was used to confirm validity and reliability of the
PLS-DA model. Additionally, R2 (proportion of variation modeled in the component) and Q2




Out of the 106 recruited cats, 12 were excluded from the study for not having met the inclusion
criteria, leaving the study population at 94 cats (46 Burmese, including 31 cats sampled in
2013, 25 MCO, and 23 Birman cats). Reasons for exclusion included non-fasting (n = 3), non-
compliance (n = 5), concurrent illness (n = 3), or increased serum biochemistry values (n = 1).
Descriptive statistics by breed for the variables age, BW, BCS, and sex distribution are shown
in Table 1. Age and sex distribution did not differ between breeds, however, BW (MCO> Bur-
mese> Birman) and BCS (Burmese > Birman) did (Table 1).
Serum biochemistry and hormonal variables. Effects of breed, BW, and BCS on the con-
centrations of creatinine, fructosamine ALAT, VLDL-TG, HDL-cholesterol, FFA, adiponectin,
Table 1. Descriptive statistics of the included cats (n = 94) by breed.
Variable1 Burmese (n = 46) Maine coon (n = 25) Birman (n = 23) P-value�
Age (years) Median 5.0 a 8.0 a 6.0 a 0.2
(IQR) (2–9) (3–10) (2–11)
BW (kg) Median 4.4 a 5.4 c 3.3 b <0.001
(IQR) (3.6–5.1) (4.6–6.6) (3.0–4.1)
BCS (scale 1–9) Median 6.0 a 5.0 a,b 5.0 b 0.014
(IQR) (5.0–6.0) (5.0–5.0) (5.0–6.0)
Sex (n) Male 2 (4%) a 2 (8%) a 3 (13%) a 0.44
Neutered male 22 (48%) 7 (28%) 5 (22%)
Female 9 (20%) 7 (28%) 8 (35%)
Neutered female 13 (28%) 9 (36%) 7 (30%)
IQR, interquartile range; BW, body weight; BCS, body condition score.
1 Data are shown as median and interquartile range and number of cats and proportions.
a,b,c Numbers within a row with different superscript letters differ from another at P < 0.05.
� P-values from one-way ANOVA.
https://doi.org/10.1371/journal.pone.0249322.t001
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insulin, and IGF-1, showed that for all variables except ALAT and FFA, a significant model
could be obtained. Breed (P< 0.0001) and BW (P< 0.0001), but not BCS (P = 0.14), had
strong overall effects in the multivariate model. There were no significant interactions present
between any of the explanatory variables. Results from the multivariate model with breed dif-
ferences are summarized in Table 2.
Body weight had significant effects on fructosamine, VLDL-TG, insulin, IGF-1, and adipo-
nectin concentrations. Increasing BW increased concentrations of fructosamine with
8.1 μmol/L per kg (P = 0.0015), VLDL-TG with 27% per kg (P< 0.0001), insulin with 20% per
kg (P = 0.024), IGF-1 with 33% per kg (P< 0.0001), and decreased the concentration of adipo-
nectin with 40.3 ng/mL per kg (P = 0.0003). Overweight cats had 20.3 μmol/L higher average
creatinine concentrations than normal weight cats (P = 0.0017).
None of the above mentioned parameters differed between Burmese cat samples collected
in 2013 and those collected in 2015 & 2016.
Metabolomics data. A significant PLS-DA model (Fig 1) successfully separated the
breeds: the first component separated MCO cats from Burmese and Birman, while the second
component separated Burmese from Birman. Out of 58 quantified metabolites 21 were found
discriminative based on their VIP along the first and second component. The discriminative
metabolites were subjected to univariate statistical analysis followed by correction for multiple
testing and 18 metabolites were reconfirmed (Table 3). The Burmese breed was characterized
by higher levels of the branched-chain amino acid (BCAA) valine, the aromatic amino acid
tyrosine, the amino acid metabolite 2-oxoisocaproic acid, and acetylcarnitine compared to
MCO cats. Additionally, 2-hydroxybutyric acid was higher and acetic acid was lower relative
to the Birman breed. Lysine and O-phosphocholine levels were lowest in Burmese cats and
significantly different from both other breeds. The metabolic fingerprint of MCO cats was
characterized by high concentrations of arginine, asparagine, methionine, creatine, dimethyl-
glycine, succinic acid and low levels of acetylcarnitine, carnitine and tyrosine compared to
Burmese and Birman cats. Birman cats showed high levels of creatinine and low taurine con-
centrations compared to Burmese and MCO cats.
Table 2. Serum biochemistry and hormonal concentrations by breed in 94 cats.
Analyte Concentration1
Burmese (n = 46) Maine coon (n = 25) Birman (n = 23) P2
Creatinine (μmol/L) 128 (119–136) a 128 (117–138) a 163 (152–174) b <0.0001
Fructosamine (μmol/L) 251 (242–260) a 238 (228–249) a 246 (234–257) a 0.004
ALAT (μkat/L) 1.1 (0.9–1.2) a 0.8 (0.6–1.0) a 1.2 (1.0–1.4) a 0.110
VLDL-TG (mmol/L) 0.19 (0.15–0.23) a 0.10 (0.07–0.12) b 0.23 (0.18–0.30) a <0.0001
HDL-cholesterol (mmol/L) 4.8 (4.4–5.3) a 4.2 (3.7–4.7) a 6.3 (5.6–7.2) b <0.0001
FFA (mmol/L) 0.52 (0.44–0.61) a 0.44 (0.36–0.53) a 0.40 (0.32–0.49) a 0.170
Adiponectin (ng/mL) 429 (390–468) a 609 (562–656) b 466 (416–516) a <0.0001
Insulin (ng/mL) 211 (157–283) a 115 (81–164) b 169 (116–247) a,b 0.036
IGF-1 (ng/mL) 660 (532–818) a 378 (292–489) b 773 (587–1018) a 0.001
ALAT, alanine aminotransferase; VLDL, very low-density lipoprotein; TG, triglycerides; HDL, high-density lipoprotein; FFA, free fatty acids; IGF, insulin-like growth
factor.
1 Concentrations are shown as estimated least square means for each breed, with 95% confidence intervals (CI). If residuals were non-normally distributed, data were
logged for analysis, and least square means were back-transformed and reported as geometric means, with 95% CI.
2 P-values represent breed differences based on results from the multivariate linear regression model including adjustments for body weight and body condition score.
a,b Numbers within a row with different superscript letters differ from another at P< 0.05.
https://doi.org/10.1371/journal.pone.0249322.t002
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Each point represents one cat. Model parameters: R2X component 1 = 0.103, R2X compo-
nent 2 = 0.074, R2Y(cum) = 0.668, Q2(cum) = 0.449; Cross-validated ANOVA: P< 0.001. Sig-
nificant metabolites are presented in Table 3.
Univariate regression analysis including adjustments for BW and BCS for each NMR
metabolite identified as discriminative between breeds, revealed that breed remained as a sig-
nificant explanatory variable for the following 15 metabolites: 2-hydroxybutyric acid, 2-oxoi-
socaproic acid, acetic acid, acetylcarnitine, arginine, asparagine, creatinine, dimethylglycine,
histidine, lysine, methionine, O-phosphocholine, succinic acid, taurine, and tyrosine (Table 4).
For the metabolites carnitine, creatine, and valine, breed did not remain significant, and the
discriminant effect was instead due to BW, BCS or a combination of the explanatory variables.
Arginine and creatine concentrations increased with 4.6 μM (P = 0.04) and 31.6%
(P< 0.0001) per kg BW, respectively. Tyrosine concentrations were affected by BCS, with
overweight cats having higher average concentrations than normal weight (P = 0.042) and
underweight (P = 0.013) cats.
Discussion
In the present study the metabolic fingerprint was compared between three breeds (Burmese,
MCO and Birman cats) and higher concentrations of biomarkers associated with insulin resis-
tance and/or diabetes were observed in Burmese cats, the breed with highest risk of developing
DM. Breed differences were also evident from serum biochemistry and hormone assays, where
breed was an important individual variable explaining the variation in the data.
In people, BCAAs (isoleucine, leucine, valine) and the aromatic amino acids tyrosine, and
phenylalanine have been identified as early biomarkers for T2DM [39]. In the present study,
Fig 1. Partial Least Square Discriminant Analysis (PLS-DA) score plot derived from Nuclear Magnetic Resonance (NMR)-based metabolomics
analysis in 63 cats by breed; Burmese (n = 15), Birman (n = 23) and Maine coon (n = 25) cats.
https://doi.org/10.1371/journal.pone.0249322.g001
PLOS ONE Differences in metabolic profiles between three cat breeds with varying risk for diabetes mellitus
PLOS ONE | https://doi.org/10.1371/journal.pone.0249322 April 22, 2021 7 / 15
the initial comparison of the metabolic fingerprint of the three cat breeds also showed higher
levels of valine, leucine, tyrosine, 3-methyl-2-oxovaleric acid (a breakdown product of isoleu-
cine) and 2-oxoisocaproic acid (a breakdown product of leucine) in Burmese cats. After
adjustment for body weight and body condition score only tyrosine and 2-oxoisocaproic acid
remained significantly different from the MCO breed, suggesting that some of the metabolic
differences are due to a high proportion of Burmese cats being overweight. Tyrosine has been
shown to be associated with T2DM and insulin resistance in people [39, 40, 54] in epidemio-
logical studies. Mechanistic studies suggest that 2-oxoisocaproic acid induces insulin secretion
in rat islets [55]. Alternatively, high levels of 2-oxoisocaproic acid, indicative of impaired
BCAA metabolism, may lead to an accumulation of toxic intermediates which have been sug-
gested to cause mitochondrial stress and impaired insulin action [56]. The higher
Table 3. Metabolites found different between the three cat breeds in 63 cats.
Burmese MCO Birman VIP VIP P3
(n = 15) (n = 25) (n = 23) comp 12 comp 22
Metabolite Concentration (μM)1 (95% CI) (95% CI)
2-Oxoisocaproic acid 5.5±0.9 a 4.3±0.9 b 4.9±1.6 a,b 1.18 (0.39) 1.16 (0.57) 0.008
Acetic acid 7.7 a 10.1 a,b 11.3 b - 1.41 (0.62) 0.002
(5.0–10.0) (8.7–12.6) (9.7–17.0)
Acetylcarnitine 4.1 a 2.6 b 3.6 a 1.88 (0.89) 1.6 (0.47) <0.001
(3.0–5.1) (2.2–3.1) (2.8–4.2)
Arginine 122.1±19.0 a 146.7±22.4 b 118.2±13.0 a 2.14 (0.53) 1.67 (0.37) <0.001
Asparagine 57.9 a 68.2 b 60.6 a 2 (0.99) 1.55 (0.85) <0.001
(50.1–66.8) (63.3–72.9) (53.2–62.7)
Carnitine 25.0 a 21.7 b 25.6 a 1.46 (1.04) 1.13 (0.86) 0.004
(23.9–28.4) (18.3–28.5) (24.3–31.1)
Creatine 9.5 a 12.2 b 8.4 a 1.23 (1.09) - 0.001
(6.3–13.7) (10.6–23.4) (7.4–12.3)
Creatinine 128.8±28.7 a 123.7±19.0 a 146.8±19.0 b 1.5 (0.87) 1.57 (0.97) 0.002
Dimethylglycine 4.1 a 5.0 b 4.1 a 1.5 (1.25) 1.26 (0.82) 0.001
(3.5–4.3) (4.5–6.4) (3.7–4.7)
Histidine 110.5±16.3 a,b 120.7±14.3 a 107.2±16.4 b - 1.03 (1.02) 0.012
Lysine 72.0 a 107.7 b 114.3 b - 1.81 (1.13) <0.001
(63.6–80.2) (93.4–138.9) (85.2–126.2)
Methionine 40.3±9.0 a 48.1±9.0 b 35.0±7.9 a 1.99 (1) 1.68 (0.66) <0.001
O-Phosphocholine 3.3±0.5 a 4.1±0.9 b 4.2±0.7 b - 1.69 (1.11) 0.001
Succinic acid 15.0 a 17.7 b 14.6 a 1.63 (1.32) 1.27 (1.13) 0.001
(12.2–17.1) (16.2–19.9) (10.2–17.6)
Taurine 295.8±86.4 a 286.6±121.5 a 193.3±89.2 b 1.93 (0.91) 1.3 (0.8) 0.003
Tyrosine 60.7±10.7 a 47.2±10.4 b 59.3±10.2 a 1.28 (0.78) 1.51 (0.75) <0.001
2-Hydroxybutyric acid 20.0±4.7 a 17.0±4.2 a,b 16.1±3.6 b - 1.28 (0.99) 0.020
Valine 183.0±28.0 a 156.2±34.2 b 176.5±36.5 a,b - 1.11 (0.58) 0.032
VIP, variable influences of projection; CI, confidence interval; MCO, Maine coon.
1 Concentrations are shown as mean with standard deviation for normally distributed data, and as median and interquartile range for non-normally distributed data.
2 VIPs (95% CI) are based on the PLS-DA model presented in Fig 1.
3 P-values represent breed differences based on univariate statistical analyses (one-way ANOVA or Kruskal-Wallis test), P< 0.013 was considered significant based on
the Benjamini-Hochberg correction for multiple testing.
a,b Numbers within a row with different superscript letters differ from another at P< 0.05, based on univariate statistics including Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0249322.t003
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concentrations of insulin in Burmese than in MCO cats may indicate insulin resistance and
thus be related to the increased risk for DM.
Also dimethylglycine, an amino acid derivative, differed in concentration between breeds,
with Burmese cats having lower concentrations than MCO cats, after adjustment for body
weight and body condition score. Low plasma levels of dimethylglycine have been associated
with higher blood glucose levels in human [57]. Additionally, higher concentrations of
2-hydrobutyric acid were observed in the Burmese compared to the MCO and Birman breed.
2-hydroxybutyric acid, derived from alpha-ketobutyrate which is produced by glutathione
anabolism and amino acid catabolism (threonine and methionine), is an early marker for insu-
lin resistance and impaired glucose regulation in people, and the underlying mechanism may
involve increased lipid oxidation and oxidative stress [58].
Acetylcarnitine, a short-chain acylcarnitine, was significantly higher in Burmese and Bir-
man cats than in MCO cats. Acetylcarnitine has been shown to be higher in T2DM patients
than in healthy controls, and high acylcarnitines have also been associated with IR in people
[59]. Acetylcarnitine concentrations were significantly correlated with plasma HbA1c in peo-
ple, which suggests that higher acetylcarnitine levels are associated with an increasing severity
of diabetes [60]. Experimental administration of acetylcarnitine improves insulin-mediated
glucose disposal [61]. Acylcarnitines are also involved in an alternative model for explaining
the obesity-induced IR focusing on intra-mitochondrial disturbances. According to this the-
ory, an overload of lipids cause an increase, rather than a decrease, in beta-oxidation, leading
to production and accumulation of acylcarnitines, which in turn interfere with insulin signal-
ing in skeletal muscle [20, 62]. Indeed, VLDL-TG were significantly higher in Burmese and
Table 4. Metabolites remaining discriminant for breeds after adjusting for body weight and body condition score.
Metabolite Concentration (μM)1 P2
Burmese Maine coon Birman
(n = 15) (n = 25) (n = 23)
2-Hydroxybutyric acid 20.5 (17.9–23.1) a 17.1 (15.1–19.1) b 16.8 (14.7–19.0) b 0.033
2-Oxoisocaproic acid 5.8 (5.0–6.5) a 4.3 (3.7–4.9) b 4.9 (4.3–5.6) a,b 0.014
Acetic acid 8.4 (5.6–11.2) a 10.9 (8.7–13.1) a,b 13.4 (11.0–15.8) b 0.011
Acetylcarnitine 4.1 (3.5–5.8) a 2.8 (2.5–3.2) b 3.5 (3.1–4.0) a 0.003
Arginine � 124.0 (113.0–134.9) a 141.6 (133.0–150.1) b 124.3 (115.0–133.6) a 0.022
Asparagine 57.0 (52.3–62.2) a 68.7 (64.1–73.5) b 58.4 (54.3–62.9) a 0.003
Creatinine 126.3 (113.6–139.0) a 120.0 (110.1–130.0) a 150.5 (139.7–161.3) b 0.0002
Dimethylglycine 3.7 (3.2–4.3) a 4.9 (4.4–5.5) b 4.3 (3.8–4.9) a,b 0.013
Histidine 111.8 (102.2–121.5) a,b 123.5 (115.9–131.0) a 107.3 (99.1–115.5) b 0.027
Lysine 70.1 (60.6–81.0) a 104.1 (92.9–116.6) b 110.1 (97.3–124.5) b <0.0001
Methionine 39.7 (34.8–45.3) a 47.8 (43.1–53.0) b 34.3 (30.7–38.4) a 0.0005
O-phosphocholine 3.1 (2.7–3.6) a 4.1 (3.8–4.5) b 4.1 (3.7–4.5) b 0.0004
Succinic acid 13.0 (11.1–15.2) a 18.0 (15.9–20.4) b 13.0 (11.4–14.9) a 0.002
Taurine 283.3 (218.7–347.9) a 292.8 (242.2–343.3) a 184.2 (129.3–239.1) b 0.007
Tyrosine x 56.5 (50.3–63.4) a 44.8 (41.0–49.1) b 58.5 (53.0–64.5) a 0.001
1 Concentrations (μM) are shown as estimated least square means for each breed, with 95% confidence intervals (CI). If residuals were not normally distributed, data
were logged for analysis, and least square means were back-transformed and reported as geometric means, with 95% CI.
2 P-value for type 3 tests of breed as fixed effect.
a,b Numbers within a row with different superscript letters differ from another at P< 0.05.
� For arginine there was an additional effect from body weight (P = 0.04).
x For tyrosine there was an additional effect from body condition (P = 0.03).
https://doi.org/10.1371/journal.pone.0249322.t004
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Birman compared to MCO cats, although the BCS was lower in both Birman and MCO than
in Burmese cats.
The concentrations of adiponectin were lowest in Burmese cats, but significantly different
only from the MCO breed. Adiponectin is an adipocyte-derived hormone, with an inconsis-
tent association with obesity in cats. Some studies have shown a negative correlation [50, 63–
66], while others did not detect associations between total adiponectin concentrations and
obesity [49, 67]. Increasing BW in our study was associated with lower adiponectin concentra-
tions, however, we did not identify BCS as an independent factor influencing adiponectin lev-
els. The three breeds in this study represent two normal-sized cat breeds, the Burmese and the
Birman, and one large-sized breed, the MCO. Adiponectin directly regulates glucose metabo-
lism and increases insulin sensitivity in people by stimulating fatty-acid oxidation, glucose
uptake, and reduces gluconeogenesis in the liver [27, 68]. In cats and people with DM, adipo-
nectin concentrations are even lower than in overweight and obese individuals, indicating that
the degree of hypoadiponectinemia is more closely related to the degree of insulin resistance
than to the degree of adiposity [25, 26, 69, 70].
The plasma metabolic profile of MCO cats was characterized by higher concentrations of
two essential amino acids, arginine and methionine [71], and one non-essential amino acid,
asparagine, compared to Burmese and Birman cats. Arginine is essential due to its crucial role
in the urea cycle to excrete ammonia. Methionine, a sulfur containing proteinogenic amino
acid, is needed as methyl-group donor and acceptor.
Breed differences for plasma biochemical analytes in cats have been reported previously,
with Birman cats displaying higher creatinine and total protein concentrations than other cats
[72]. Birman cats had significantly higher creatinine concentrations than the Burmese and
MCO cats also in the present study. The reasons for these findings are unclear. Creatinine was
also associated with BCS, with higher concentrations seen in overweight cats than in both nor-
mal weight and underweight cats. Serum creatinine is a byproduct of muscle metabolism, and
it is possible that the underweight cats in our study had less muscle mass which might explain
part of the effect of BCS on creatinine.
The present study is the first using a metabolomics approach to assess differences between
cat breeds, with the comparatively large number of samples being a strength. Metabolomics
uses relatively cheap and noninvasive techniques to produce large amounts of data and thus
shows potential to improve disease diagnostics [73]. In the search for biomarkers, many
metabolites can be measured, and once a biomarker is identified and validated, other simpler
methodologies can be used in a clinical setup. An improved understanding of the variation in
metabolism between different breeds may thus enable identification of new markers related to
abnormal metabolism/insulin resistance and potentially facilitate the development of therapies
to improve glucose tolerance in cats of high-risk breeds. Although DM in people shows great
heterogeneity not only between but also within different types, and not all variants of T2DM
may have feline counterparts [74], the results also support the use of the cat as a model for
T2DM in people.
Conclusions
To our knowledge, this is the first study including NMR data from a comparably large cohort
of healthy cats of three breeds with different risk of developing DM; the Burmese, MCO and
Birman. We found significant differences in the metabolic profiles between the included cat
breeds, based on an NMR metabolomics approach, serum biochemistry analyses and hormone
immunoassays. Our results indicate that Burmese cats have a metabolic fingerprint similar to
that in people with IR. An improved understanding of the variation in metabolism between
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different breeds may facilitate the development of therapies to improve glucose tolerance in
cats of high risk breeds.
Acknowledgments
The authors thank the Swedish Burmese Cat Club for their collaboration, and Claudia von
Brömssen for statistical advice.
Author Contributions
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Investigation: Malin Öhlund, Elisabeth Müllner, Ali Moazzami, Ulrika Hermansson, Ann
Pettersson.
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